RAPP (Rapport Therapeutics) Change In Payables And Accrued Expense : $1.49 Mil (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics Change In Payables And Accrued Expense?

Rapport Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was $0.52 Mil. It means Rapport Therapeutics's Accounts Payable & Accrued Expense increased by $0.52 Mil from Dec. 2024 to Mar. 2025 .

Rapport Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was $0.03 Mil. It means Rapport Therapeutics's Accounts Payable & Accrued Expense increased by $0.03 Mil from Dec. 2023 to Dec. 2024 .

Rapport Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Rapport Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics Change In Payables And Accrued Expense Chart

Rapport Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

6.24

0.03

Rapport Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial					-0.95	-0.88	0.36	1.50	0.52

Rapport Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.49 Mil.

Rapport Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Rapport Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapport Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1325 Boylston Street, Suite 401, Boston, MA, USA, 02215

Website

https://www.rapportrx.com

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.